-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Ranked Among the Top 100 Chinese Pharmaceutical Companies by Main Business Revenue in 2024
Category:
发布时间：2025-07-06
【概要描述】
In July, Changping District of Beijing is awash with vibrant blossoms and brimming with vitality. On July 6, the 42nd National Pharmaceutical Industry Information Annual Conference and the 2025 Beijing–Changping Life Sciences Forum, organized by the China Pharmaceutical Industry Information Center, were grandly held here.
In July, Changping District of Beijing is awash with vibrant blossoms and brimming with vitality. On July 6, the 42nd National Pharmaceutical Industry Information Annual Conference and the 2025 Beijing–Changping Life Sciences Forum, organized by the China Pharmaceutical Industry Information Center, were grandly held here. During the conference, the highly anticipated list of the Top 100 Chinese pharmaceutical companies by main business revenue for 2024 was officially unveiled, with Shijiazhuang Sihua Pharmaceutical Group proudly making the cut at No. 59. The company was also recognized as an outstanding case among industrial enterprises in China’s pharmaceutical R&D pipeline for 2025, further enhancing the profile of Shijiazhuang’s biopharmaceutical industry.
According to available information, the National Pharmaceutical Industry Information Annual Conference is the industry’s premier annual event, having been successfully held for 41 consecutive sessions and widely regarded as a “barometer of the pharmaceutical sector.” The 42nd edition of the conference unveiled the 2024 ranking of the top 100 Chinese pharmaceutical companies by main business revenue, based primarily on objective data from the Comprehensive Volume of the China Pharmaceutical Industry Statistical Yearbook, with the aim of establishing benchmarks for the industry.
In recent years, the Group has remained firmly committed to high-quality development as its top priority, taking it as its mission to research, develop, and produce more “Made-in-China” pharmaceuticals. Grounded in national strategies and market demands, the Group has vigorously implemented an innovation-driven strategy, relentlessly pursuing innovation with a sense of urgency and momentum. It has continuously promoted the deep integration and coordinated development of the innovation chain, talent chain, industrial chain, and supply chain, and actively built a modern industrial system led by innovative drugs, with specialty chemical drug formulations and active pharmaceutical ingredients as its core, and extended by high-end pharmaceutical packaging materials and specialized biologics. Through these efforts, the Group has consistently fostered and developed new drivers of productivity, while technological innovation and digital transformation have powerfully underpinned the integrated development of “active pharmaceutical ingredients plus formulations.” In 2024, the Group filed applications for a total of 133 new products, of which 82 were approved, maintaining a leading position in the industry in both the number of filings and approvals. As a result, the foundation for the company’s green, high-quality, innovation-driven development has grown ever stronger, and its innovative influence and market competitiveness have reached new heights.
During the annual conference, Su Xuejun, Chairman of the Group, was invited to attend the plenary forum, where he engaged in a dialogue with leading industry executives on the theme of “Collaborative Innovation Models for Industrial Chains: Value Coexistence and Ecosystem Integration,” jointly discussing the challenges and opportunities facing the high-quality development of the biopharmaceutical industry. Su Xuejun pointed out that the biopharmaceutical sector is currently at a critical juncture of transformation and upgrading. In the face of multiple challenges—including market shifts, policy adjustments, and technological advancements—pharmaceutical companies must align closely with industry development trends, strengthen innovation-driven growth, and actively promote the deep integration of the four key chains—industrial chain, innovation chain, supply chain, and value chain—to continuously enhance collaborative innovation capabilities across the entire pharmaceutical value chain, seize strategic advantages in development, and comprehensively bolster resilience and vitality.
Relevant leaders of the group attending the meeting stated that they will always uphold the original mission of “producing high-quality medicines for the people,” proactively benchmark against industry leaders, continuously strengthen their innovation capabilities, intensify the integration of their competitive strengths, refine mechanisms for the efficient commercialization of innovative achievements, steadily consolidate the foundation for integrated development spanning active pharmaceutical ingredients and finished dosage forms, facilitate both domestic and international dual circulation, comprehensively enhance the company’s core competitiveness, and strive to make greater contributions to advancing the high-quality development of Shijiazhuang’s biopharmaceutical industry and to building a Healthy China.
According to the organizers, this year’s annual conference is themed “Exploring Life, Co-Creating the Future,” and encompasses policy briefings, cutting-edge scientific research, academic symposia, trend analysis, and industry resource matchmaking. It brings together representatives from government regulatory agencies, enterprises, research institutes, medical institutions, and other stakeholders, who will engage in a series of forums, promotional events, and closed-door sessions to jointly explore pathways for industrial innovation and promote the high-quality development of the pharmaceutical ecosystem. Shijiazhuang Sihua Pharmaceutical Group Ranked Among the Top 100 Chinese Pharmaceutical Companies by Main Business Revenue in 2024
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091